STOCK TITAN

[SCHEDULE 13D/A] STAAR SURGICAL CO SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13D/A

Amendment No. 38 to a Schedule 13D reports that Broadwood-affiliated reporting persons collectively beneficially own 13,545,391 shares of STAAR Surgical Co., representing 27.4% of the common stock. The filing amends prior disclosures to state that on September 24, 2025 the reporting persons filed a definitive proxy statement and a GREEN proxy card to solicit votes AGAINST the Proposed Merger and the Compensation Proposal at the special meeting. The reporting persons also issued a press release and a letter to stockholders and launched the campaign website www.LetSTAARShine.com. The September 24 Letter is attached as Exhibit 99.1 and incorporated by reference.

Modifica n. 38 a una Schedule 13D riporta che le persone che riportano affiliate a Broadwood detengono collettivamente in modo beneficiario 13,545,391 azioni di STAAR Surgical Co., pari al 27,4% del capitale sociale comune. La dichiarazione modifica le comunicazioni precedenti per indicare che il 24 settembre 2025 le persone riportanti hanno presentato una definitiva proposta di procura e una scheda proxy GREEN per sollecitare i voti CONTRO la fusione proposta e la proposta di retribuzione durante l'assemblea speciale. Le persone riportanti hanno inoltre emesso un comunicato stampa e una lettera agli azionisti e hanno lanciato il sito della campagna www.LetSTAARShine.com. La Lettera del 24 settembre è allegata come Esibizione 99.1 e incorporata per riferimento.

Enmienda No. 38 a un Schedule 13D informa que las personas reportantes vinculadas a Broadwood poseen colectivamente de manera beneficiosa 13,545,391 acciones de STAAR Surgical Co., que representan el 27,4% del capital social común. La presentación enmienda divulgaciones previas para indicar que el 24 de septiembre de 2025 las personas reportantes presentaron una declaración de delegación definitiva y una papeleta proxy GREEN para solicitar votos EN CONTRA de la Fusión Propuesta y de la Propuesta de Compensación en la reunión especial. Las personas reportantes también emitieron un comunicado de prensa y una carta a los accionistas y lanzaron el sitio web de la campaña www.LetSTAARShine.com. La Carta del 24 de septiembre se adjunta como el Anexo 99.1 e incorporada por referencia.

개정 제38호가 Schedule 13D에 보고된 Broadwood 계열 보고자들이 통합적으로 13,545,391주의 STAAR Surgical Co. 주식을 보유하고 있으며, 이는 보통주 총발행주식의 27.4%에 해당한다고 보고합니다. 제출서는 기존 공시를 수정하여 2025년 9월 24일에 보고자들이 확정 의결권 대리선언 및 GREEN 대리카드를 제출하여 제안된 합병 및 보상 제안에 대한 표결을 반대한다고 밝힙니다. 보고자들은 또한 보도자료와 주주에게 보내는 서한을 발표하고 캠페인 웹사이트 www.LetSTAARShine.com를 개설했습니다. 9월 24일의 서한은 Exhibit 99.1로 첨부되어 있으며 참고로 포함됩니다.

Amendement n° 38 à un Schedule 13D indique que les personnes signalant affiliées à Broadwood détiennent collectivement, de manière bénéficiaire, 13 545 391 actions de STAAR Surgical Co., représentant 27,4% du capital social ordinaire. Le dépôt modifie les divulgations antérieures en indiquant que le 24 septembre 2025, les personnes signalantes ont déposé une déclaration de procuration définitive et une carte-proxy GREEN afin de solliciter les voix CONTRE la fusion proposée et la proposition de rémunération lors de l’assemblée spéciale. Les personnes signalantes ont également publié un communiqué de presse et une lettre aux actionnaires et lancé le site de la campagne www.LetSTAARShine.com. La lettre du 24 septembre est jointe en tant qu’Exhibit 99.1 et est intégrée par référence.

Änderung Nr. 38 zu einem Schedule 13D berichtet, dass Broadwood-verbundene meldende Personen gemeinschaftlich als nutzbringend 13.545.391 Anteile an STAAR Surgical Co. besitzen, was 27,4% des Stammkapitals entspricht. Die Einreichung ändert frühere Offenlegungen dahingehend, dass am 24. September 2025 die meldenden Personen eine endgültige Proxy-Erklärung und eine GREEN-Proxy-Karte eingereicht haben, um bei der Sonderversammlung gegen die vorgeschlagene Fusion und den Vergütungsplan zu stimmen. Die meldenden Personen haben außerdem eine Pressemitteilung und einen Brief an die Aktionäre veröffentlicht und die Kampagnen-Website www.LetSTAARShine.com gestartet. Der Brief vom 24. September ist als Exhibit 99.1 beigefügt und durch Bezugnahme incorporated.

التعديل رقم 38 إلى الجدول 13D يفيد بأن الأشخاص المبلغين المرتبطين بـ Broadwood يمتلكون بشكل منفعة مجتمعياً 13,545,391 سهماً من STAAR Surgical Co.، وهو ما يمثل 27.4% من رأس المال العادي. يقدم الملف تعديلاً للإفصاحات السابقة ليشير إلى أنه في 24 سبتمبر 2025 قدمت الأطراف المبلغة بيان تفويض نهائي وبطاقة توكيل GREEN للتصويت ضد الاندماج المقترح واقتراح التعويض في الاجتماع الخاص. كما أصدر الأطراف المبلغة بياناً صحفياً وخطاباً للمساهمين وأطلقوا موقع الحملة www.LetSTAARShine.com. يحتوي خطاب 24 سبتمبر على Exhibit 99.1 مرفقاً ومضمناً بالإشارة.

修订第38号对 Schedule 13D 的报告显示,Broadwood 相关报告人合计受益拥有 13,545,391 股 STAAR Surgical Co. 普通股,约占 27.4%。该备案修改了先前披露,称在 2025 年 9 月 24 日,报告人提交了一个最终代理声明和一张 GREEN 代理卡,以在特别股东大会上就拟议的合并及薪酬方案投票时< b>反对。报告人还发布了新闻稿、致股东的信函,并上线了竞选网站 www.LetSTAARShine.com。9 月 24 日的致信作为 Exhibit 99.1 附件,按参考并入。

Positive
  • Significant ownership position: Reporting persons collectively hold 13,545,391 shares (27.4%), giving them substantial influence.
  • Formal proxy campaign: Filing of a definitive proxy statement and GREEN proxy card demonstrates an organized, transparent solicitation effort.
  • Public engagement: Issuance of a press release, stockholder letter, and campaign website (www.LetSTAARShine.com) increases visibility and shareholder outreach.
Negative
  • Opposition to Proposed Merger: Reporting persons are soliciting votes AGAINST the Merger Agreement and the Compensation Proposal, creating uncertainty around closing.
  • Potential for contested vote: A public proxy campaign could lead to prolonged shareholder dispute and delay in transaction execution or integration plans.

Insights

TL;DR: Broadwood, holding a large 27.4% stake, has launched a formal proxy campaign to oppose STAAR's proposed merger.

The filing documents a coordinated, public activist effort by Broadwood Partners, Broadwood Capital and Neal C. Bradsher to solicit proxies against both the merger agreement and related compensation arrangements. A 27.4% beneficial ownership stake is substantial and sufficient to materially influence shareholder votes or force negotiations. The attached definitive proxy and public campaign materials indicate the situation will be contested and may delay or alter the merger outcome.

TL;DR: The filing signals governance conflict and a shareholder challenge that could affect board-approved transaction timing and terms.

The amendment emphasizes process and conflict concerns raised by the reporting persons and formalizes their opposition with a GREEN proxy card and public outreach. Filing an Exhibit 99.1 letter and launching a website shows an organized solicitation effort focused on persuading other shareholders. This is a material governance development with direct implications for shareholder approval votes and potential revisions to transaction or compensation terms.

Modifica n. 38 a una Schedule 13D riporta che le persone che riportano affiliate a Broadwood detengono collettivamente in modo beneficiario 13,545,391 azioni di STAAR Surgical Co., pari al 27,4% del capitale sociale comune. La dichiarazione modifica le comunicazioni precedenti per indicare che il 24 settembre 2025 le persone riportanti hanno presentato una definitiva proposta di procura e una scheda proxy GREEN per sollecitare i voti CONTRO la fusione proposta e la proposta di retribuzione durante l'assemblea speciale. Le persone riportanti hanno inoltre emesso un comunicato stampa e una lettera agli azionisti e hanno lanciato il sito della campagna www.LetSTAARShine.com. La Lettera del 24 settembre è allegata come Esibizione 99.1 e incorporata per riferimento.

Enmienda No. 38 a un Schedule 13D informa que las personas reportantes vinculadas a Broadwood poseen colectivamente de manera beneficiosa 13,545,391 acciones de STAAR Surgical Co., que representan el 27,4% del capital social común. La presentación enmienda divulgaciones previas para indicar que el 24 de septiembre de 2025 las personas reportantes presentaron una declaración de delegación definitiva y una papeleta proxy GREEN para solicitar votos EN CONTRA de la Fusión Propuesta y de la Propuesta de Compensación en la reunión especial. Las personas reportantes también emitieron un comunicado de prensa y una carta a los accionistas y lanzaron el sitio web de la campaña www.LetSTAARShine.com. La Carta del 24 de septiembre se adjunta como el Anexo 99.1 e incorporada por referencia.

개정 제38호가 Schedule 13D에 보고된 Broadwood 계열 보고자들이 통합적으로 13,545,391주의 STAAR Surgical Co. 주식을 보유하고 있으며, 이는 보통주 총발행주식의 27.4%에 해당한다고 보고합니다. 제출서는 기존 공시를 수정하여 2025년 9월 24일에 보고자들이 확정 의결권 대리선언 및 GREEN 대리카드를 제출하여 제안된 합병 및 보상 제안에 대한 표결을 반대한다고 밝힙니다. 보고자들은 또한 보도자료와 주주에게 보내는 서한을 발표하고 캠페인 웹사이트 www.LetSTAARShine.com를 개설했습니다. 9월 24일의 서한은 Exhibit 99.1로 첨부되어 있으며 참고로 포함됩니다.

Amendement n° 38 à un Schedule 13D indique que les personnes signalant affiliées à Broadwood détiennent collectivement, de manière bénéficiaire, 13 545 391 actions de STAAR Surgical Co., représentant 27,4% du capital social ordinaire. Le dépôt modifie les divulgations antérieures en indiquant que le 24 septembre 2025, les personnes signalantes ont déposé une déclaration de procuration définitive et une carte-proxy GREEN afin de solliciter les voix CONTRE la fusion proposée et la proposition de rémunération lors de l’assemblée spéciale. Les personnes signalantes ont également publié un communiqué de presse et une lettre aux actionnaires et lancé le site de la campagne www.LetSTAARShine.com. La lettre du 24 septembre est jointe en tant qu’Exhibit 99.1 et est intégrée par référence.

Änderung Nr. 38 zu einem Schedule 13D berichtet, dass Broadwood-verbundene meldende Personen gemeinschaftlich als nutzbringend 13.545.391 Anteile an STAAR Surgical Co. besitzen, was 27,4% des Stammkapitals entspricht. Die Einreichung ändert frühere Offenlegungen dahingehend, dass am 24. September 2025 die meldenden Personen eine endgültige Proxy-Erklärung und eine GREEN-Proxy-Karte eingereicht haben, um bei der Sonderversammlung gegen die vorgeschlagene Fusion und den Vergütungsplan zu stimmen. Die meldenden Personen haben außerdem eine Pressemitteilung und einen Brief an die Aktionäre veröffentlicht und die Kampagnen-Website www.LetSTAARShine.com gestartet. Der Brief vom 24. September ist als Exhibit 99.1 beigefügt und durch Bezugnahme incorporated.






If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D




Comment for Type of Reporting Person:
Box 11 - Does not include 2,532 Shares over which Mr. LeBuhn does not have direct or indirect beneficial ownership. Such shares are held in three separate irrevocable trusts for Mr. LeBuhn's daughters in which Mr. LeBuhn has no voting or dispositive power and disclaims any beneficial ownership interest in such shares.


SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D


BROADWOOD PARTNERS, L.P.
Signature:/s/ Neal C. Bradsher
Name/Title:Neal C. Bradsher, President of Broadwood Capital, Inc.
Date:09/26/2025
Broadwood Capital, Inc.
Signature:/s/ Neal C. Bradsher
Name/Title:Neal C. Bradsher, President
Date:09/26/2025
Neal C. Bradsher
Signature:/s/ Neal C. Bradsher
Name/Title:Neal C. Bradsher
Date:09/26/2025
Richard T. LeBuhn
Signature:/s/ Richard T. LeBuhn
Name/Title:Richard T. LeBuhn
Date:09/26/2025
Natalie R. Capasso
Signature:/s/ Natalie R. Capasso
Name/Title:Natalie R. Capasso
Date:09/26/2025
Raymond A. Myers
Signature:/s/ Raymond A. Myers
Name/Title:Raymond A. Myers
Date:09/26/2025
Jason J. Martin
Signature:/s/ Jason J. Martin
Name/Title:Jason J. Martin
Date:09/26/2025

FAQ

What stake does Broadwood report in STAAR Surgical (STAA)?

The reporting persons collectively beneficially own 13,545,391 shares, representing 27.4% of STAAR common stock.

What action did Broadwood take on September 24, 2025 regarding STAA?

They filed a definitive proxy statement and GREEN proxy card to solicit votes AGAINST the Proposed Merger and the Compensation Proposal and issued a press release and stockholder letter.

Where can I read Broadwood's letter to STAAR stockholders?

The September 24 Letter is attached as Exhibit 99.1 to the Schedule 13D amendment and is incorporated by reference; it is available on the SEC website.

What materials did Broadwood publish to support their campaign?

They published a definitive proxy statement, a GREEN proxy card, a press release containing a stockholder letter, and launched www.LetSTAARShine.com.

Will Broadwood's filing affect the special meeting vote on the merger?

The filing indicates Broadwood intends to solicit shareholder votes against the merger and compensation proposals, which is a material development that could affect the special meeting outcome.
Staar Surg

NASDAQ:STAA

STAA Rankings

STAA Latest News

STAA Latest SEC Filings

STAA Stock Data

1.33B
49.04M
0.56%
111.03%
8.06%
Medical Instruments & Supplies
Ophthalmic Goods
Link
United States
MONROVIA